Compare ARCC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARCC | BBIO |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 15.9B |
| IPO Year | 2004 | 2019 |
| Metric | ARCC | BBIO |
|---|---|---|
| Price | $18.84 | $82.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 25 |
| Target Price | $21.36 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 4.4M | 3.2M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $5.77 | $89.45 |
| Revenue Next Year | $2.29 | $73.78 |
| P/E Ratio | $143.92 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $17.40 | $42.09 |
| 52 Week High | $22.76 | $93.42 |
| Indicator | ARCC | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 60.60 |
| Support Level | $18.37 | $62.39 |
| Resistance Level | $19.35 | $84.85 |
| Average True Range (ATR) | 0.29 | 2.88 |
| MACD | 0.00 | -0.21 |
| Stochastic Oscillator | 30.34 | 37.94 |
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.